FARMINGDALE, N.Y., March 26, 2013 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, announces a new clinical paper accepted for publication by "Neurosurgery," the journal of the Congress of Neurological Surgeons, a well-respected, peer-reviewed journal circulated to neurosurgeons throughout the world. The paper is entitled "Ultrasonic Bone Scalpel for Osteoplastic Laminoplasty in the Resection of Intradural Spinal Pathology: Case Series and Technical Note," and is authored by Parker, Kretzer, Recinos, et al., and is based on surgeries performed at the Johns Hopkins Hospital, Baltimore, Maryland. Laminoplasty, like laminectomy, is a procedure aimed at relieving pressure on the spinal cord, caused by a variety of conditions. Laminoplasty is often preferred versus laminectomy as it may offer certain longer term advantages, such as decreasing the incidence of progressive kyphosis (curvature) of the spine and facilitating post-operative osteo-integration, which is the forming of functional and structural integrity between native bone and artificial implants.

The objective going into the 40-patient study was to determine the safety and technical feasibility of using the BoneScalpel for osteoplastic laminoplasty based on the ability of the device to precisely cut bone while preserving the underlying soft tissues and the potential positive impact on post- surgical osteo-integration. Successful laminoplasty was carried out in all 40 cases with no incidence of spinal instability during the follow-up period. A primary soft tissue complication was reduced by more than 40% versus previously reported institutional rates.

The Misonix BoneScalpel which was used to perform the study, is a novel ultrasonic osteotome (bone cutting device) used for safe, tissue-selective bone dissection that encourages en-bloc bone removal and refined osteotomies while sparing elastic soft tissue structures. Most users report that the surgical field is relatively bloodless and clean. Loss of viable bone is minimal and controllable. The BoneScalpel has been used extensively for bone removal in the cervical, thoracic and lumbar spine, including deformity surgery.

"In clinicals performed around the world, the BoneScalpel has been shown to result in less bleeding, greater visibility, less bone loss and greater patient safety. We are gratified to continue to receive reports such as this one, which demonstrate impressive clinical results with the Misonix BoneScalpel when used in delicate spine surgery," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "It is our privilege to provide state-of-the-art ultrasonic surgical technology to prestigious institutions, such as Johns Hopkins, throughout the world."

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.